Literature DB >> 8811119

Metabolites of 5-fluorouracil, alpha-fluoro-beta-alanine and fluoroacetic acid, directly injure myelinated fibers in tissue culture.

T Akiba1, R Okeda, T Tajima.   

Abstract

The neurotoxicity of two 5-fluorouracil (5-FU) derivatives, tegafur (FT) and carmofur (HCFU), which selectively induce leukoencephalopathy involving the cerebral white matter in humans and vacuolation of myelinated fibers in dogs and cats, was examined in vitro. The common metabolites of these drugs, alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA), were added to the medium of cultured murine cerebellar myelinated fibers. On day 1 of exposure to 7 microM FBAL and FA, which corresponds to their blood concentrations 2 h after oral administration of 10 mg.kg-1 HCFU to dogs that induced central nervous system vacuolation after 30 days, partial splits of the myelinic intraperiod line were observed by electron microscopy. On days 4-7, phase contrast microscopy revealed spindle-shaped swelling and granulation of myelin and electron microscopy demonstrated prominent dissociation of the myelinic intraperiod line with monolocular and multilocular vacuolation. More severe changes, such as myelin loss, were found in cultures exposed to a higher concentration (70 microM) of FBAL and FA, but no remarkable neuronal, astrocytic or oligodendrocytic changes occurred. Quantitative evaluation of myelin injury by electron microscopy revealed significant toxicity of FBAL and FA, at concentrations of 7 and 70 microM, on day 4. However, groups treated with 0.7 microM FBAL and FA, 5-FU (7 microM) and controls exposed to beta-alanine and acetic acid concentrations of 0.7, 7 and 70 microM showed no marked injury. We concluded that these anticancer drug metabolites injure myelin fibers directly, resulting in vacuolation due to myelin splitting and destruction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8811119     DOI: 10.1007/s004010050482

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  8 in total

1.  Hyperperfusion on magnetic resonance imaging in acute chemotherapy-related leukoencephalopathy.

Authors:  Lisa Michael El-Hakam; Melissa Beth Ramocki; James John Riviello; Anna Illner
Journal:  J Child Neurol       Date:  2010-04-02       Impact factor: 1.987

Review 2.  Magnetic resonance imaging patterns of treatment-related toxicity in the pediatric brain: an update and review of the literature.

Authors:  Maria Camilla Rossi Espagnet; Luca Pasquini; Antonio Napolitano; Antonella Cacchione; Angela Mastronuzzi; Roberta Caruso; Paolo Tomà; Daniela Longo
Journal:  Pediatr Radiol       Date:  2016-12-09

3.  Medication neurotoxicity in children.

Authors:  Ramesh S Iyer; Apeksha Chaturvedi; Sumit Pruthi; Paritosh C Khanna; Gisele E Ishak
Journal:  Pediatr Radiol       Date:  2011-07-23

4.  Candidate mechanisms for capecitabine-related hand-foot syndrome.

Authors:  Gérard Milano; Marie-Christine Etienne-Grimaldi; Mireille Mari; Sandra Lassalle; Jean-Louis Formento; Mireille Francoual; Jean-Philippe Lacour; Paul Hofman
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

Review 5.  Diffusion-weighted MRI in neuro-oncology.

Authors:  Joachim M Baehring; Robert K Fulbright
Journal:  CNS Oncol       Date:  2012-11

6.  5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine.

Authors:  Katsuki Muneoka; Yoshio Shirai; Naoyuki Yokoyama; Toshifumi Wakai; Katsuyoshi Hatakeyama
Journal:  Int J Clin Oncol       Date:  2005-12       Impact factor: 3.850

7.  Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system.

Authors:  Ruolan Han; Yin M Yang; Joerg Dietrich; Anne Luebke; Margot Mayer-Pröschel; Mark Noble
Journal:  J Biol       Date:  2008-04-22

8.  Methotrexate induced leucoencephalopathy: A stroke mimic.

Authors:  Tushar D Gosavi; Mohammed Tauqeer Ahmad; Lai-Heng Lee; Shih-Hui Lim
Journal:  Ann Indian Acad Neurol       Date:  2013-07       Impact factor: 1.383

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.